
Bosses of hospitals that spend too much or treat too few will not get pay rise
Bosses of hospitals with long waiting times or that overspend their budget will be denied pay rises in a tough new drive by Wes Streeting to improve the NHS's performance.
Senior executives in England's 215 NHS trusts and 42 integrated care boards will also receive bonuses for cutting waiting lists under plans the health secretary has unveiled.
Streeting insisted the 'carrot and stick' performance management regime would lead to the health service adopting tactics already widely used in business to incentivise better performance.
But NHS organisations warned that withholding pay could backfire, be seen as 'punishing' NHS leaders and deter talented bosses from working in trusts facing major challenges.
The 'very senior managers (VSMs) pay framework' will apply to thousands of chief executives but also to deputy chief executives, chief operations officers, chief financial officers and other top-level roles.
Under it, the chief executive of a trust that does badly operationally or financially will no longer receive their annual salary uplift, which last year gave VSMs up to an extra £15,000.
But it would also give bosses who push through major improvements to their trust's performance, under either measure, bonuses of up to £30,000 as a reward for making substantial progress.
Chief executives who take over a struggling trust could also be given a £45,000 payment for doing so.
'Some of the best businesses and most effective organisations across Britain and the world reward their top talent so they can keep on delivering. There's no reason why we shouldn't do the same in our NHS,' said Streeting.
'We will reward leaders who are cutting waiting times and making sure patients get better services. But bonuses and pay rises will be a reward and not a right.'
He hopes the move will tackle the 'postcode lottery' in the quality of care across the NHS and deliver shorter waiting times.
But Matthew Taylor, the chief executive of the NHS Confederation, warned that using VSM pay in this way could unfairly penalise bosses whose trust's performance is dictated by events outside their control.
'While we understand there should not be rewards for failure, we are concerned that some of the measures could be seen as punishing NHS leaders,' he said.
'The challenges facing NHS organisations can sometimes be due to historic or systemic issues rather than poor leadership.'
Managers in Partnership (MiP), which represents many VSMs, said cuts to trust workforce numbers initiated by the new NHS England boss, Sir Jim Mackey, as part of a 'reset' of the service's finances would make it 'very difficult' for local leaders to deliver good performance.
'Most provider trusts are taking very hard decisions about services and clinical posts, all of which are going to affect care quality. The reset also requires trusts to take out large numbers of management and system jobs, which will weaken management grip, at least in the short term,' said Jon Restell, MiP's chief executive.
Sign up to First Edition
Our morning email breaks down the key stories of the day, telling you what's happening and why it matters
after newsletter promotion
Meanwhile a record 16,644 people in England – 320 a week – died last year after waiting at least 12 hours in overcrowded A&E units before being admitted to a bed, the latest figures show.
That was 2,745 more than the 13,919 who did so the year before, according to an analysis by the Royal College of Emergency Medicine (RCEM), which represents A&E doctors.
The 16,644 'excess deaths' occurred among patients who spent 12 hours in A&E before getting a bed in a specialist ward of the hospital and then died within 30 days of their arrival.
'It's heartbreaking that the number of people losing their lives directly related to long stays in A&E is rising, not falling. It's a source of national shame that we are going backwards on this and not forwards,' said Dr Adrian Boyle, the RCEM president.
Labour MP and former shadow health minister Rosena Allin-Khan, who is also an A&E doctor, said: 'The situation in emergency departments across the country has been dire. We have all had to treat patients in corridors and cupboards and the indignity of it is scarring.
'Staff often put on a brave face, trying their best to make people comfortable, but it takes its toll on everyone involved. That is why I am pleased the government are committed to bringing down waiting lists.'
The MP has helped set up a new all-party parliamentary group on emergency care, involving MPs and peers from different parties, which launches on Thursday at Westminster.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mail
8 minutes ago
- Daily Mail
Kate Middleton carries it - now you can too! Aspinal of London's iconic handbags are now up to 50% off - don't miss these sale picks from just £50
Aspinal of London have huge reductions across their site with up to 50 per cent off, including many items for under £50. Known for their timeless elegance and craftsmanship, Aspinal has been a favourite among royals. The brand has been seen worn by Kate Middleton, Princess Beatrice, and Zara Tindall, solidifying its status as a staple of refined British style. And with up to half-price on some of their most popular designs, including handbags and leather travel items, there's never been a better time to invest in a new bag for summer ahead of any holidays, weddings or special events. With such impressive reductions, it's also a great time to shop for gifts for Father's Day. Highlights for him include the Mount Street Washbag - now a massive 50 per cent off in the Aspinal sale and the Aspinal of London 8 Card Billfold Wallet, now under £50. Aspinal of London Midi London Tote You can't go wrong with the classic and wholly elegant signature London Leather Tote Bag. A versatile everyday companion, the timeless tote can be carried by the soft top handles or worn over one shoulder. This gorgeous racing green is perfect for all year round, too. £357 (save £238) Shop Aspinal of London Camera Crossbody A crossbody bag is a brilliant way to go hands free yet have all your essentials on you and Aspinal of London does this so well with the Camera Crossbody Bag. £207 (save £88) Shop Aspinal of London Stella Satchel Crossbody Wherever your summer trips take you, whether it's mid-week in the city to weekends out in the country, the Stella Satchel is a super chic way of carrying your essentials - and now for half-price. £275 (save £275) Shop Aspinal of London Regent Tote Taking you from work to the weekend, the Regent Tote Bag is semi-structured and lightweight with a spacious interior with the capacity to hold a lightweight 14-inch laptop along with an open slip pocket for your valuables. £255 (save £170) Shop Aspinal of London City Leather Folio Case Aspinal of London do brilliant leather accessories that would make for gorgeous gifts, and with Father's Day around the corner, the City Leather Folio Case is a great idea. Especially as it's on sale for 40 per cent off. £150 (save £100) Shop Aspinal of London Classic 5oz Leather Hip Flask No just £39, it's a great time to shop the Classic 5oz Leather Hip Flask. A brilliant wedding gift or gift for Father's Day you can also get this engraved to add an extra special touch. £38 (save £17) Shop Aspinal of London Portobello Crossbody A take on the saddle bag, the Aspinal Portobello bag is handcrafted from full-grain leather and secured by the brand's signature letterbox closure. £248 (save £248) Shop Aspinal of London 8 Card Billfold Wallet If you're looking for a gift for him, then the Aspinal of London 8 Card Billfold Wallet is a classic gift that's sure to be welcomed by anyone. A classic, the simple design is handcrafted from full-grain leather, and features eight credit card slots, a full-length compartment for notes and two hidden pockets for receipts or other cards. £49 (save £50) Shop


Fashion United
8 minutes ago
- Fashion United
Nobody's Child e-commerce director exits for Dubai brand Squatwolf
Chris Bishop, the e-commerce and digital director of Nobody's Child, has exited the British fashion brand to take up a similar role at Dubai-based sportswear company Squatwolf. Bishop announced his appointment on LinkedIn, where he said he was 'happy to share that I'm starting a new position as e-commerce director at Squatwolf'. Until May 2025, Bishop had been in his now former role at Nobody's Child since September 2022. He had joined the brand after serving as a self-employed business, e-commerce and marketing consultant over the course of six years. During this time, he worked with companies ranging from high growth startups to 100 million pound turnover firms. Among these were names like UK-based bicycling company Sigma Sports, where he was interim chief marketing officer, and fashion rental platform MyWardrobeHQ, as interim e-commerce director. In his new position, Bishop will work alongside Squatwolf founders Anam Khalid and Wajdan Gul on accelerating the growth of the gymwear brand. Founded in 2016, Squatwolf has experienced significant growth in its lifetime, expanding beyond the Middle East to serve consumers in over 120 countries, its LinkedIn page states. In 2023, the company raised 30 million dollars in a Series B funding round, which was to be used to expand its omnichannel presence and develop its product lines.


Reuters
11 minutes ago
- Reuters
Novartis' Pluvicto shown to slow prostate cancer in earlier setting
FRANKFURT, June 2 (Reuters) - Novartis (NOVN.S), opens new tab said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier disease stage for a drug technology that the drugmaker has pioneered. The Swiss drugmaker reported a late-stage trial showed a "clinically meaningful benefit" in progression-free survival with a positive trend in overall survival in patients with metastatic prostate cancer that still responds to standard hormone therapy. Almost all of those patients ultimately progress to a form of cancer that no longer responds to hormone therapy, a setting where Pluvicto is already approved, the company added. "These data suggest using (Pluvicto) in an earlier disease setting," Novartis said, adding that this could address a significant unmet need. Novartis only provided a brief summary of trial results and said details would be presented at a medical conference and that it would likely request regulatory approval for wider use in the second half of the year. Pluvicto is part of a class of drugs that combines cell-killing radioactive particles with molecules that attach themselves to tumours, where Novartis has a leading position. The drug saw first-quarter revenue gain 20% to $371 million.